Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 14/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1928376 | 0.99 | PTGS1 (0.49) | PTGS1PTGS2CNR2CA1CA2 | |
| SCHEMBL1927808 | 0.84 | PTGS1 (0.48) | PTGS1PTGS2CNR2CA1CA2 | |
| SCHEMBL1926735 | 0.83 | PTGS1 (0.47) | PTGS1PTGS2CNR2CA1CA2 | |
| SCHEMBL6960693 | 0.82 | PTGS1 (0.46) | PTGS1PTGS2CNR2CA1CA2 | |
| SCHEMBL1927474 | 0.75 | CNR2 (0.67) | PTGS1PTGS2CNR2CA1CA2 | |
| SCHEMBL6954872 | 0.75 | MEN1 (0.53) | PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL1928142 | 0.74 | CNR2 (0.66) | PTGS1PTGS2CNR2CA1CA2 | |
| SCHEMBL1930188 | 0.72 | PTGS1 (0.45) | PTGS1PTGS2CA1CA2 | |
| SCHEMBL6960978 | 0.72 | TP53 (0.42) | PTGS1PTGS2 | |
| SCHEMBL18003580 | 0.71 | MAPT (0.48) | PTGS1PTGS2CNR2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101559053-A | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2009-10-21 | — | — | CN | claimed |
| CN-100488506-C | 5-membered heterocyclic derivatives, their preparation and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2009-05-20 | — | — | CN | claimed |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | LASSAUNIERE PIERRE-ETIENNE CHA | 2008-06-19 | — | — | US | claimed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | claimed |
| CN-1391474-A | 5-membered heterocyclic derivatives, their preparation and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2003-01-15 | — | — | CN | claimed |
| EP-1223933-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-24 | — | — | EP | claimed |
| WO-2001026656-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND USE THEREOF AS MONOAMINE OXIDASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-04-19 | — | — | WO | claimed |
| EP-1589007-B1 | 5-membered heterocycle derivatives, production thereof and their use as medicaments | IPSEN PHARMA (FR) | 2015-06-03 | — | — | EP | disclosed |
| US-8288560-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2012-10-16 | — | — | US | disclosed |
| EP-1228760-B1 | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | IPSEN PHARMA (FR) | 2011-08-31 | — | — | EP | disclosed |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | IPSEN PHARMA S.A.S. (FR) | 2011-07-14 | — | — | US | disclosed |
| US-7956075-B2 | Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain. | IPSEN PHARMA S.A.S. (FR) | 2011-06-07 | — | — | US | disclosed |
| CN-101559053-A | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2009-10-21 | — | — | CN | disclosed |
| EP-1589007-A2 | 5-membered heterocycle derivatives, production thereof and their use as medicaments | Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S) SAS (FR) | 2005-10-26 | — | — | EP | disclosed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | disclosed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | disclosed |
| CN-1391474-A | 5-membered heterocyclic derivatives, their preparation and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2003-01-15 | — | — | CN | disclosed |
| EP-1228760-A2 | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-07 | — | — | EP | disclosed |
| EP-1223933-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001026656-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND USE THEREOF AS MONOAMINE OXIDASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, OPRK1 | PTGS1 263/4885PTGS2 364/4885CNR2 22/4885 |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OPRK1, HCN1, P2RX7 | PTGS1 138/4885PTGS2 366/4885CNR2 15/4885 |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | OXER1, OPRL1, CHRNA7 | PTGS1 269/4885PTGS2 427/4885CNR2 27/4885 |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, P2RX7 | PTGS1 460/4885PTGS2 733/4885CNR2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.